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Embryonic Stem Cells Improve Cardiac Function in Doxorubicin-Induced 
Cardiomyopathy Mediated Through Multiple Mechanisms
Dinender K. Singla, Aisha Ahmed, Reetu Singla, and Binbin Yan
Biomolecular Science Center, Burnett School of Biomedical Sciences, College of Medicine,  
University of Central Florida, Orlando, FL, USA
Doxorubicin (DOX) is an effective antineoplastic agent used for the treatment of a variety of cancers. 
Unfortunately, its use is limited as this drug induces cardiotoxicity and heart failure as a side effect. There is 
no report that describes whether transplanted embryonic stem (ES) cells or their conditioned medium (CM) in 
DOX-induced cardiomyopathy (DIC) can repair and regenerate myocardium. Therefore, we transplanted ES 
cells or CM in DIC to examine apoptosis, fibrosis, cytoplasmic vacuolization, and myofibrillar loss and their 
associated Akt and ERK pathway. Moreover, we also determined activation of endogenous c-kit+ve cardiac stem 
cells (CSCs), levels of HGF and IGF-1, growth factors required for c-kit cell activation, and their differentia-
tion into cardiac myocytes, which also contributes in cardiac regeneration and improved heart function. We 
generated DIC in C57Bl/6 mice (cumulative dose of DOX 12 mg/kg body weight, IP), and animals were treated 
with ES cells, CM, or cell culture medium in controls. Two weeks post-DIC, ES cells or CM transplanted hearts 
showed a significant ( p < 0.05) decrease in cardiac apoptotic nuclei and their regulation with Akt and ERK 
pathway. Cardiac fibrosis observed in the ES cell or CM groups was significantly less compared with DOX 
and cell culture medium groups ( p < 0.05). Next, cytoplasmic vacuolization and myofibrillar loss was reduced 
( p < 0.05) following treatment with ES cells or CM. Moreover, our data also demonstrated increased levels 
of c-kit+ve CSCs in ES cells or CM hearts and differentiated cardiac myocytes from these CSCs, suggesting 
endogenous cardiac regeneration. Importantly, the levels of HFG and IGF-1 were significantly increased in 
ES cells or CM transplanted hearts. In conclusion, we reported that transplanted ES cells or CM in DIC hearts 
significantly decreases various adverse pathological mechanisms as well as enhances cardiac regeneration that 
effectively contributes to improved heart function.
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loss and vacuolar degeneration, and (c) fibrosis. These 
changes result in rearrangement of heart tissue, increased 
wall stress, and insufficient systolic contractility in cardiac 
myocytes (12,22,27,38). Importantly, the collagen synthesis 
that is increased in DIC is also associated with concurrent 
extracellular matrix (ECM) degradation via activation of 
matrix metalloproteinases (MMPs) (12,33,38). Numerous 
studies have demonstrated inhibiting doxorubicin- induced 
cardiac myocyte apoptosis in DIC using various agents 
such as erythropoietin and antioxidants (11–13). However, 
DIC is a major health problem; therefore, accurate identifi-
cation of novel therapeutic approaches is still warranted.
Over the past decade, cell transplantation studies have 
demonstrated significant interest as a potential option to treat 
distinct heart diseases including DIC (1,9,39). Published 
studies demonstrate significant improvement in cardiac 
function in DIC following adult stem cell transplantation 
(1,9,39). Moreover, these studies proclaimed minimal or no 
INTRODUCTION
Doxorubicin (DOX) is an antineoplastic antibiotic 
vastly used antitumor agent for a diversity of malignancies 
(22,27). However, the clinical use of this drug is restricted 
due to a severe, dose-dependent, acute cardio toxicity that 
may progress to irreversible chronic cardiomyopathy and 
congestive heart failure. DOX-induced cardio myopathy 
(DIC) has been well published in human and animal stud-
ies. Even though, the precise mechanism of DIC is unclear, 
antitumor activity of DOX is relayed to be distinct from the 
mechanisms of induced cardio myopathy. DIC appears to 
involve multifactorial and complex disease mechanisms; 
however, oxidative stress plays a major role in this cardio-
toxicity. DIC is characterized by contractile dysfunction 
and rhythm disturbances that lead to congestive heart fail-
ure in a time-dependent manner (22,27). Moreover, devel-
opment of heart failure includes (a) death of both cardiac 
myocytes and nonmyocyte myocardial cells, (b) myofibril 
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successful engraftment of transplanted cells (1,39). There is 
no data yet attainable that describes the ability of embryonic 
stem (ES) cells or their factors released to repair and regen-
erate DIC; however, ES cells have a distinct advantage as 
they are unique in the potential to differentiate into many 
body cell types compared with their counterpart adult stem 
cells (28). Therefore, in the present study, we hypothesized 
that transplanted ES cells or their conditioned medium 
(CM), containing cytoprotective factors, will inhibit DIC. 
We present data in this study on transplanted ES cells or CM 
that inhibit cardiac apoptosis, fibrosis, cytoplasmic vacu-
olization, and myofibril loss, typical characteristics of DIC. 
Additionally, we also determined significant increased levels 
of hepatocyte growth factor (HGF) and insulin growth factor 
(IGF-1) in hearts transplanted with ES cells or CM, required 
in activating c-kit+ve cardiac stem cells (CSCs). Moreover, 
increased numbers of c-kit+ve CSCs were predominantly 
observed in the same HGF and IGF-1 hearts. Finally, we 
observed significant improvement in cardiac function fol-
lowing ES cells or CM transplantation, suggesting multiple 
mechanisms are required to blunt DIC. 
MATERIALS AND METHODS
ES Cells and Preparation of CM
Mouse ES cells expressing green fluorescence pro-
tein (GFP) were maintained using our standard pro-
tocol as previously described (30,32). In brief, cells 
were plated 24 h on gelatinized tissue culture plates 
in Dulbecco’s modified Eagle’s medium (DMEM) 
containing essential ingredients such as fetal bovine 
serum (FBS), leukemia inhibitory factor (LIF), glu-
tamine, penicillin/streptomycin, sodium pyruvate, and 
b-mercaptoethanol. For ES-CM, cell culture medium 
was replaced with cell culture medium without LIF. 
After 48 h, released factors containing cell super-
natant was removed, filtered (0.2-mm filter, Millipore, 
USA), and used to inject sterile CM as we previously 
published (30,32).
Animals and Experimental Protocol
 All the animals described in this study are approved 
by University of Central Florida animal care commit-
tee. C57Bl6 mice were divided into five different study 
groups: control, normal saline, DOX, DOX + cell culture 
(CC) medium, DOX + ES cells, or DOX + CM. There 
were n = 6–8 animals in each of the five study groups.
DOX was administered in three equal injections in 
mice (4 mg/kg/injection IP) on alternate days over the 
period of 1 week for a cumulative dose of 12 mg/kg. 
For treatment groups, CC medium (400 µl/injection and 
the total of three injections), ES cells (5 ´ 105 ES cells/
injection and total of three injections), or ES-CM (400 
µl/injection and total of three injections) was injected 
during DOX treatment on alternative days. For example, 
DOX or normal saline in controls 400 µl/injection was 
given on Monday, Wednesday, and Friday, whereas 
treatment groups, CC medium, ES cells, or ES-CM were 
given on Tuesday, Thursday, and Saturday. After the last 
injection of treatment groups, animals were examined 
for heart function using echocardiography and were 
sacrificed at day (D) 14 by administering pentabarbi-
tol (40 mg/kg, IP). Furthermore, half of the heart tissue 
was fixed in 4% paraformaldehye, whereas the other 
half was saved in RNA later to perform biochemical and 
ELISA assays. 
Identification of Apoptotic Nuclei and  
Caspase-3 Staining
Apoptotic nuclei in heart sections with or without cell 
transplantation groups were identified using a commer-
cially available terminal deoxynucleotidyl transferase 
dUTP nick end labeling (TUNEL assay kit; TMR red; 
Roche Applied Biosystems, IN, USA) as per detailed 
instructions available with the kit. Moreover, we have 
published this protocol in our previous studies (29). 
Next, we identified colabeling of TUNEL-positive apo-
ptotic nuclei with proapoptotic caspase-3 as well as with 
sarcomeric cardiac a-actin to determine if apoptosis does 
occur in cardiac myocytes. In brief, TUNEL-stained sec-
tions were stained with primary antibodies; active anti-
caspase-3 rabbit polyclonal (1:1,000; Cell Signaling) 
and sarcomeric cardiac a-actin mouse monoclonal 
antibodies (1:30; Sigma). Following incubations, sec-
tions were washed with PBS and labeled with secondary 
antibodies: anti-rabbit Alexa 568 (Invitrogen) or anti-
mouse Alexa 488 (MOM kit, vector laboratories). Total 
nuclei were stained blue with DAPI (4′,6-diamidino-
2-phenylindole) present in the mounting Vectashield 
medium. Positively stained cells were examined, and 
photomicrographs were prepared with an Olympus fluo-
rescence microscope and a LEICA laser scanning confo-
cal microscope. Red stained apoptotic nuclei present in 
the left ventricular area of the heart were examined, and 
quantifications were determined by two blind observers 
in four to five random areas in one to two heart sections 
from six to eight different hearts as published (29). To 
determine percentage of apoptotic nuclei per section, 
we calculated using the formula: number of apoptotic 
nuclei/total number of nuclei per section and then mul-
tiply by 100. Percentage of apoptotic nuclei data was 
examined under 20´ magnification. 
Caspase-3 Activity 
Heart homogenates were prepared from different 
DOX and ES cell-treated groups. Caspase-3 activity was 
performed using a caspase-3 colorimetric activity assay 
kit from BioVision (CITY, CA, USA) as we reported 
recently (5). Protein concentrations were measured in 
ES CELLS IN DOXORUBICIN-INDUCED CARDIOMYOPATHY 1921
the supernatant using a Bio-Rad assay. Caspase-3 activ-
ity was performed as per the instructions provided in the 
kit and measured at 405 nm in a microtiter plate reader. 
Caspase-3 activity was calculated and plotted in the form 
of arbitrary units (A.U.).
Phosphorylated Akt Activity 
Phosphorylated Akt (p-Akt) and phosphorylated extra-
cellular signal-regulated kinases 1/2 (p-ERK 1/2) activi-
ties were examined using commercially available kits 
(Exalpha Biologicals, Inc., Maynard, MA). In brief, tis-
sues were homogenized as described beforehand, and 
p-Akt and p-ERK 1/2 were quantified according to man-
ufacturer’s instructions. The reactions were developed, 
and the color reactions were measured at 450 nm using a 
microtiter plate reader for each ELISA. p-Akt and p-ERK 
1/2 protein data were plotted as ng/mg tissue and arbi-
trary units (A.U.), respectively. 
Determination of HGF and IGF-1 in Heart Tissue in DIC
Hearts were isolated; homogenates were prepared with 
the assay buffer provided with the kit. Using our standard 
Bio-Rad assay, total protein concentrations were deter-
mined. Commercially available kits, HGF (B-Bridge 
International, CA) and IGF-1 (R&D, Minneapolis, USA), 
were purchased and used to measure HGF and IGF-1 lev-
els in the DIC hearts with or without treatment groups. 
These kits are based on the ELISA sandwich assay, which 
was performed in accordance with the kit instructions. 
HGF and IGF-1 concentrations in the samples were ana-
lyzed from the standard curve performed according to the 
kit directions.
Determination of Myofibrillar Loss, Cytoplasmic 
Vacuolization, and Fibrosis
Hearts were rapidly removed, placed in iced saline, 
fixed in 4% buffered formalin and embedded in paraf-
fin as described previously (29). 5-µm serial sections 
were cut and deparaffinized by incubation in xylene. 
Rehydration was accomplished by sequential incuba-
tion in 100%, 95%, and 70% ethanol for 5 min each 
at room temperature, followed by washing in distilled 
water and then phosphate-buffered saline (PBS) for 
5–10 min. Heart sections were stained with commonly 
used H&E and Mason’s trichrome protocols. Two to 
three H&E-stained heart sections were examined com-
pletely for the evaluation of myofibrillar loss and cyto-
plasmic vacuolization. Qualitative data scale, developed 
to determine cytoplasmic vacuolization and myofibril-
lar loss, varies from 0 to 2. If left ventricular (LV) 
heart section showed no signs of myofibrillar loss and 
cytoplasmic vacuolization then score was graded as 0, 
whereas if significant portion of the section had myo-
fibrillar loss and cytoplasmic vacuolization then slide 
was graded as 2. To determine cardiac fibrosis, sec-
tions were stained with Masson’s trichrome. Cardiac 
fibrosis predominantly present in the left ventricle was 
examined and quantified by measuring the total blue 
area per mm2 in each section using freely available 
ImageJ, NIH program.
Identification of c-Kit+ve Cells and Their Differentiation 
Into Cardiac Myocytes
Sections were deparaffinized as described above. To 
block nonspecific staining, sections were incubated in 
humidified chamber in 10% normal goat serum (NGS) 
from 30 min to 1 h at room temperature. Following incu-
bation, sections were washed and incubated with pri-
mary rabbit polyclonal antibody anti-c-kit (Santa Cruz 
Biotechnologies) and sarcmomeric cardiac α-actin mouse 
monoclonal antibody (Sigma), diluted with 10% NGS, 
for an hour at 37°C. Sections were washed in PBS and 
incubated with secondary antibody Alexa Fluor 568 or 
antimouse fluorescein isothiocyanate (FITC) available in 
the MOM kit (Vector Laboratories) for 1 h. Heart sec-
tions were washed and mounted with Vectashield anti-
fade medium (containing nuclear stain DAPI; Vector 
Laboratories). Quantitative analysis of c-kit+ve cells was 
determined on heart sections from four to six different hearts 
using Olympus and confocal fluorescence microscope. 
Echocardiographic Analysis
We routinely performed 2D echocardiography on 
mice using a Sonos 5500 ultrasonograph with a 15-MHz 
transducer (Philips, Andover, MA). Mice were sedated 
with ketamine (100 mg/kg, IM), the chest was shaved and 
maintained on a heated platform to control temperature, 
and placed in a supine or left lateral decubitus position to 
measure left ventricular (LV) functions using 2D echocar-
diography. For quantification of LV dimensions and wall 
thickness, we digitally recorded 2D clips and M-mode 
images in a short axis view from the mid-LV at the tips 
of the papillary muscles. End diastolic and systolic LV 
diameter, as well as anterior and posterior wall (AW and 
PW, respectively) thickness, was measured on M-mode 
images using the leading edge-to-leading edge conven-
tion. LV fractional shortening and mass were calculated 
from LV cross-sectional area in 2D short axis view as 
[(LVDdiastole – LVDsystole  / LVDdiastole)] ´  100 and LV mass 
with formula [1.05 ´  (PWdiastole + AWdiastole + LVDdiastole)3 – 
(LVDdiastole)3]. Relative wall thickness was calculated as 
2 ´  PWdiastole / LVDdiastole. 
Data Analysis
Values were presented as means ± SEM. One-way 
analysis of variance (ANOVA) was performed followed 
by Dunn’s test. Differences between values were consid-
ered statisticaly significant when p < 0.05.
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RESULTS
Effects of Transplanted ES Cells or CM on  
Apoptosis in DIC
Figure 1 (A–O) shows apoptotic positive nuclei 
with TUNEL staining. Right panel histogram shows 
there was a significant (p < 0.05) increase in TUNEL-
positive nuclei in DOX and DOX + CC medium-treated 
hearts compared with normal saline controls. This sig-
nificant increase in apoptotic nuclei were attenuated in 
DOX + CM or DOX + ES cell groups, suggesting pro-
tective effects of CM or ES cell treatments (p < 0.05) 
(Fig. 1P). Next, we wanted to investigate whether 
apoptotic nuclei are present in the cardiac myocytes as 
well as stained positive with active caspase-3 staining, 
considered as a hallmark of apoptosis. Therefore, heart 
sections from all groups were stained with TUNEL, 
colabeled with sarcomeric cardiac a-actin and active 
caspase-3 antibody. Figure 2 (A–E) shows that TUNEL-
stained nuclei were positive with active caspase-3 as 
well as suggesting apoptosis does occur in cardiac myo-
cytes as confirmed with sarcomeric cardiac a-actin. 
Moreover, we performed a  caspase-3 activity assay as 
shown in Figure 2F. Significantly increased caspase-3 
activity in DOX and DOX + CC hearts compared with 
controls were attenuated following CM or ES cell trans-
plantation. However, apoptosis and caspase-3 activities 
were not significant between DOX + CM and DOX + ES 
cell groups.
CM or ES Cells Regulate Akt and ERK Pathways in DIC 
Apoptosis has been regulated with increased or 
decreased expressions of Akt and ERK signaling path-
ways in ischemic heart diseases (8,17,32). Therefore, 
we examined effects of these pathways in the DIC and 
their modulation with transplanted CM or ES cells. 
Phosphorylated Akt was significantly reduced in the 
DOX and DOX + CC groups compared with normal con-
trols, suggesting a decrease in cell survival. Moreover, 
hearts transplanted with CM or ES cells had significant 
increased activation of p-Akt compared to DOX and 
DOX + CC (Fig. 3A). Moreover, our data suggest phos-
phorylated ERK1/2 is significantly increased in DOX and 
DOX + CC groups compared with control. A significant 
decrease in ERK1/2 was observed in hearts transplanted 
with CM or ES cells (p < 0.05) (Fig. 3B).
CM or ES Cells Inhibit Fibrosis, Cytoplasmic 
Vacuolization, and Myofibrillar Loss
To determine the effect of transplanted CM or ES 
cells on cardiac fibrosis, we stained heart sections with 
Masson’s trichrome. In Figure 4 (A–E), the blue areas 
show fibrotic tissue present in the DOX-treated hearts 
with or without CM or ES cells. Our quantitative data 
suggest that DOX and DOX + CC hearts demonstrated a 
significant (p < 0.05) increase in blue area, an indicative of 
cardiac fibrosis (Fig. 4F). However, this increased fibro-
sis was reduced following CM or ES cell transplantation 
Figure 1. Transplanted conditioned medium (CM) or embryonic stem (ES) cells inhibit cardiac myocyte apoptosis at 2 weeks post- 
doxorubicin-induced cardiomyopathy (DIC). Representative photomicrographs of total nuclei stained with DAPI in blue (A–E) and 
terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-stained apoptotic nuclei in red (F–J) and merged nuclei 
in pink (K–O); scale bar: 50 µm. Right: histogram (P) shows quantitative apoptotic nuclei per section from control (C), DOX (D), 
D + culture medium (D + CC), D + CM, and D + ES cell groups. Data are from the n = 6–9 animals (*p < 0.05 compared to C; #p < 0.05 
vs. D and D + CC). 
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Figure 2. Effects of transplanted CM or ES cell on cardiac myocyte apoptosis and caspase-3 activity. Representative photos of heart 
section labeled with sarcomeric cardiac α-actin (A), apoptotic nuclei stained with TUNEL in purple (B), section stained with active 
caspase-3 antibody (C), total nuclei stained with DAPI in blue (D), and merged image (E) demonstrating apoptosis appearing in car-
diac myocytes and positive with active caspase-3. Boxed area in (E), demonstrates colocalization of sarcomeric cardiac α-actin, active 
caspase-3 (yellow area), TUNEL-positive nucleus, and DAPI. Scale bar: 25 µm. Bottom right histogram (F) shows total apoptotic 
nuclei from five to eight different animals each group (*p < 0.001 vs. C, #p < 0.05 vs. D and D + CC). A.U., arbitrary units.
Figure 3. Phospho-Akt and extracellular signal regulated kinase (ERK) alterations following CM or ES cell transplantation in the DIC. 
(A) Performed quantitative analysis of phospho-Akt regulation. (B) Quantitative levels of phosphorylated ERK upregulation (*p < 0.05 
compared to C; #p < 0.05 vs. D and D + CC). Data are from heart homogenates of n = 4–6 animals/group. A.U., arbitrary units. 
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(Fig. 4F). Therefore, relative increased amounts of viable 
cardiac muscle were observed in the DOX + CM or ES 
cells (Fig. 4D, E) compared with DOX or DOX + CC 
groups (Fig. 4B, C). 
Cyoplasmic vacuolization and myofibrillar loss, a 
well-recognized characteristic of DIC, were examined to 
strengthen our findings. In normal saline-treated control, 
hearts show full-length cardiac myocytes with intact cyto-
plasmic structure as well as well-organized myofibrillars 
(Fig. 5A). In contrast, DOX- or DOX + CC-treated hearts 
demonstrate clear evidence of loss of cytoplasm as well 
as myofibrils in many cardiac myocytes (Fig. 5B, C), and 
this increased cytoplasmic vacuolization and myofibril-
lar loss was significantly reduced following CM or ES 
cells treatments (Fig. 5D, E). Moreover, our semiquan-
titative data suggest significant (p < 0.05) increase in 
cytoplasmic vacuolization and myofibrillar loss in DOX 
and DOX + CC hearts (Fig. 5F, G). Following treatments 
with CM or ES cells in DIC, hearts showed significantly 
reduced amounts of cytoplasmic vacuolization and 
myofibrillar, suggesting a decrease in cardiomyopathy 
(Fig. 5F, G). 
c-Kit+ve Cells and Their Progenitor Cells Following CM 
or ES Cell Transplantation
To determine activated cardiac endogenous c-kit+ve 
cells and their differentiation into cardiac myocytes to 
define their role in cardiac regeneration, we examined 
c-kit+ve cells and their colabeling with sarcomeric car-
diac a-actin to stain cardiac myocytes in heart sections 
with or without CM or ES cell transplantation in DIC. 
Figure 6 (A–D) shows positively stained c-kit+ve cells as 
well as c-kit+ve cells combined with cardiac myocyte-
specific sarcomeric cardiac a-actin, suggesting some 
of the c-kit+ve cells differentiate into cardiac myocytes. 
Quantitative c-kit+ve cells in DOX or DOX + CC sig-
nificantly increased (p < 0.05) compared with normal 
saline controls, suggesting injury released cytokine 
Figure 4. Effects of transplanted CM or ES cell on cardiac fibrosis. Photomicrographs show histological sections stained with Mason’s 
trichrome after 2 weeks of DOX treatment of different hearts from each group. Blue area shows extent of fibrosis in different condi-
tions: control, C (A); DOX, D (B); D + CC (C); D + CM (D); and D + ES cells (E). Scale bar: 50 µm. (F) Histogram shows quantitative 
cardiac fibrosis in post-DIC with or without treatment groups. Data are from six to eight animals (*p < 0.05 compare to C; #p < 0.05 vs. 
D and D + CC).
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and growth factors may have triggered c-kit+ve cells 
(Fig. 6E). Moreover, c-kit+ve cells were further signifi-
cantly increased in CM or ES cells groups compared 
with respective controls (Fig. 6E).
Levels of HGF and IGF-1 Following CM or  
ES Cells Transplantation
Following an increase in c-kit+ve cells in CM or ES 
cell groups in DIC, we determined the levels of HGF 
and IGF-1, a growth factor considered to be an activa-
tor of c-kit+ve cells. Our data demonstrate that heart tis-
sue homogenates prepared from CM- or ES cell-treated 
hearts have significant increased levels of HGF and IGF-1 
(Fig. 6F, G). Thus, increased HGF and IGF-1 levels sug-
gest that these factors released into DIC hearts following 
CM or ES cell transplantation may also contribute to the 
stimulation and differentiation of the CSCs that play a 
role in regeneration. 
No Evidence of Teratoma Formation Following ES Cell 
Transplantation in DOX Cardiomyopathy
To determine whether teratoma were present following 
ES cell transplantation, H&E and Masson’s trichrome-
stained heart, lung, and liver sections were examined at 
2 weeks post-DOX treatment. No evidence of teratoma 
formation was observed at 2 weeks in the heart, lung, 
and liver. Figure 7 is representative of these sections at 
2 weeks post-DOX-treated hearts. 
Improvement in LV Function Following CM or  
ES Cells Transplantation
M-mode echocardiography was used to determine the 
effect of CM or cell transplantation on LV size and func-
tion in mice at 2 weeks post-DOX treatment. Fractional 
shortening was improved by CM and ES cell trans-
planted hearts compared with DOX or DOX + CC groups 
(Fig. 8A). Additionally, CM and ES cells also demon-
strated significantly improved ejection fraction (Fig. 8B). 
Moreover, the increased LVIDs in DOX and DOX + CC 
groups was significantly (p < 0.05) (Fig. 8C) blunted fol-
lowing CM or ES cell transplantation.
DISCUSSION
Cell therapy has been widely examined in various animal 
and human cardiac diseases (9,15,16,20,21,24,25). Animal 
studies have successfully manifested significant improve-
ment in cardiac function (24,25). Human embryonic stem 
cell-derived vascular cells and bone marrow-derived mul-
tipotent progenitor cells following transplantation in the 
porcine infarcted heart improved cardiac function (36,37). 
Figure 5. Effects of transplanted CM or ES cell on cytoplasmic vacuolization and myofibrillar loss. Photomicrographs show histo-
logical sections stained with H&E staining after 2 weeks of DOX treatment of different hearts from each group. In the representative 
enlarged area, the arrow head indicates cytoplasmic vacuolization whereas the arrow shows myofibrillar loss. These cytoplasmic 
vacuo lization and myofibrillar loss areas in cardiac myocytes were determined in different conditions: C (A), D (B), D + CC (C), 
D + CM (D), and D + ES cells (E). Scale bar: 50 µm. (F) Histogram shows semiquantitative cytoplasmic vacuolization. (G) Determines 
myofibrillar loss in post-DIC with or without treatment groups. Data are from five to eight animals (*p < 0.05 compare to C; #p < 0.05 vs. 
D and D + CC).
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Moreover, bone marrow-derived stem cells or combined 
therapy with cardio myocytes inhibits doxorubicin-induced 
heart failure in rabbits (7,15,16). Unfortunately, adult stem 
cell transplanted clinical studies provided contentious 
reports on the improvement of cardiac function (9,21). 
Therefore, the use of ES cells may be an optimal cell 
type, with a wide potential for cell differentiation and 
unique in characteristics as released factors from these 
cell types are quite different compared with adult stem 
cells. Moreover, there is no data yet available that deter-
mines the effects of CM or ES cells on DIC. Therefore, 
we hypothesize that transplanted CM or ES cells will 
inhibit multiple pathological mechanisms in DIC and will 
improve associated cardiac function. 
In the present study, we used a very clinical relevant 
DIC cardiomyopathy model, which is well established 
by various investigators (4,26,27). Importantly, DOX as 
administered in the present study demonstrates cardiac 
apoptosis, regulation of apoptotic-mediated Akt/ERK path-
ways, cardiac fibrosis, cytoplasmic vacuolization, myo-
fibrillar loss, and decrease in cardiac function in terms of 
fractional shortening and ejection fraction as deliberated 
by echocardiography. These alterations construct DIC as 
observed in cancer patients treated with DOX (4,26,27). 
Figure 6. Effects of transplanted CM or ES cell on cardiac stem cells (CSCs) and their differentiation into cardiac myocytes. Heart 
section stained with sarcomeric cardiac α-actin showing all stained cardiac myocytes in green (A), resident CSCs were identified by 
anti-c-kit antibody labeling in red (B), and nuclei are stained with DAPI in blue (C). Merged image indicating presence of CSCs and 
the positive staining with cardiac α-actin (D, green, red, and blue). Bottom left arrow indicates differentiated CSCs, whereas dashed 
arrow in right top panel shows CSCs positive with c-kit staining. Scale bar: 50 µm. (E) Histogram shows quantitative cardiac progenitor 
cells in post-DIC hearts from C, D, D + CC, D + CM, and D + ES cells groups. Data are from four to five animals (*p < 0.05 compared to 
C; #p < 0.05 vs. D and D + CC). (F) Histogram shows hepatocyte growth factor (HGF) data analysis performed in different DIC groups. 
(G) Histogram shows levels of insulin-like growth factor (IGF)-1 in the DIC hearts with or without treatment groups. Data are from 
four to five animals (*p is non significant compared to C; #p < 0.05 vs. D and D + CC). 
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Therefore, we report that the DIC model in the present 
study is in accordance with published reports (4,26,27). 
The major findings of the present study is that transplan-
tation of the CM or ES cells in DIC results in significant 
attenuation of various pathological mechanisms such as 
(1) inhibition of cardiac myocyte apoptosis, (2) inhibited 
apoptosis involving phosphoinositol-3-kinase (PI3K)/Akt 
and ERK pathways, (3) significantly attenuated cardiac 
fibrosis, (4) inhibition of cytoplasmic vacuolization and 
myofibrillar loss, (5) activation of c-kit+ve CSCs and their 
role in cardiac regeneration, (6) increased levels HGF and 
IGF-1 growth factors required for c-kit+ve cells activation, 
and (7) ultimately improved cardiac function.
Apoptosis is an elemental part of normal organ devel-
opment (2,14). Recently, presence of apoptosis has been 
notified to regulate various diseases, including DIC (2, 
13,14). We and others have reported that apoptosis is a 
significant contributor in the development and progres-
sion of DIC (4,13,14,22). The data on apoptosis in this 
investigation were established with TUNEL staining as 
well as by measuring caspase-3 activities. We also dem-
onstrate that hearts transplanted with CM or ES cells have 
a significantly reduced amount of apoptosis. Additionally, 
we show that apoptosis does occur in cardiac myocytes 
as evidenced by colabeling of active caspase-3 with 
TUNEL-positive nuclei. Moreover, our data authenticate 
with the previously published data in DIC and infarcted 
hearts (2,4,13,14,22). As per the best of our knowledge, 
we are the first to report that transplanted CM or ES cells 
suppress apoptosis in DIC. 
Next, to comprehend mechanisms by which CM or 
ES cells inhibit apoptosis in DIC, we explored the role 
of PI3K/Akt and ERK pathways. The PI3K/Akt path-
way controls regulation of various cellular processes, 
including cell growth, proliferation, and survival (6,23). 
In the present study, we imply that DOX treatment sig-
nificantly decreases levels of Akt. This reduction in Akt 
was reversed following treatment with CM or ES cells, 
suggesting a role of Akt in cell survival in DIC hearts. 
In contrast, the role of ERK pathway is not well defined 
Figure 7. Representative photomicrographs of H&E-stained heart sections from DOX + ES cell group shows no evidence of teratoma 
formation in the heart, lung, and liver post-DIC at 2 weeks. Original magnification: 10´.
Figure 8. Transplanted CM or ES cells in DIC improve cardiac function at 2 weeks. (A) Average echocardiographic left ventricular 
fractional shortening. (B) Ejection fraction. (C) Left ventricular interior systolic diameter (LVIDs) for different treatment groups. 
*p < 0.05 compared to C; #p < 0.05 versus D and D + CC.
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in assorted heart diseases and considered controversial 
as it has been shown to be actively involved in cell sur-
vival, hypertrophy, and cell death (18,23,32). However, 
the expression levels of ERK1/2 have been increased in 
the rat hearts at 4 h post-DOX treatment, whereas this 
level was decreased at 24 h and 3 weeks posttreatment 
(19). Our data suggest upregulation of ERK pathway in 
DOX-treated hearts, suggesting ERK may induce hyper-
trophy or cell death at 2 weeks in DIC. Interestingly, this 
increase in ERK pathway was significantly reversed in 
the hearts treated with CM or ES cells. Varied difference 
in ERK1/2 in post-DIC can be explained as (1) we used 
injected DOX 12 mg/kg cumulative dose over the period 
of 1 week whereas previous report injected 15 mg/kg 
over the period of 2 weeks (19), which may have gen-
erated some variation in the induced cardiomyopathy, 
which also alters cell signaling. Moreover, authors exam-
ined levels of ERK1/2 at 1–24 h and 3 weeks post-DIC 
(19) compared with our study as we report ERK1/2 levels 
at 2 weeks post-DIC.
Next, we scrutinized whether transplanted CM or ES 
cells can inhibit cardiac fibrosis in the post-DIC hearts. 
Cardiac fibrosis, a major contributor to end-stage heart 
failure, is the result of heightened levels of various protei-
nases such as MMPs as well as a decrease in their inhibitors 
(tissue inhibitor metalloproteinases, TIMPs), which leads 
to ECM degradation, collagen protein deposition, harden-
ing of the contractile heart muscle, and eventually, cardiac 
dysfunction (10). We report in the current study that fibro-
sis considerably exists in DIC hearts. However, presence 
and amount of fibrosis in DIC compared with infarcted 
hearts is substantially different (10). Observed fibrosis in 
the DIC hearts was patchy and widely distributed. In con-
trast, infarcted hearts exhibit a transmural infarction and 
significant extent of fibrosis in the confined area (10). The 
accurate mechanism for the stimulation of fibrosis in the 
DIC hearts remains obscure, whereas transforming growth 
factor b1 (TGF-b1) actively induces fibrosis in the infarcted 
hearts (10). Next, our data for the first time reports that car-
diac fibrosis in the DIC hearts was significantly attenuated 
following CM or ES cell transplantation. We published 
recently that factors released from ES cells contain anti-
fibrotic factor TIMP-1 and inhibit apoptosis in the H9c2 
cells (30,32). We also published that apoptosis and fibrosis 
in the infarcted hearts was significantly reduced follow-
ing CM transplantation (31). Moreover, inhibited apop-
tosis in the H9c2 cells was mediated by Akt pathway but 
not by ERK pathway (32). However, we suggest that DIC 
involves both Akt and ERK pathways in the regulation of 
cardiac remodeling in the present study. Therefore, this 
raises further questions whether inhibited apoptosis and 
fibrosis in DIC following CM or ES cell transplantation 
involves similar mechanisms. 
Cytoplasmic vacuolization and myofibrillar loss in car-
diac myocytes is well established, and recorded characteris-
tics of DIC were ascertained in animal models and patients 
(26,27). Our present study also demonstrates the appear-
ance of cytoplasmic vacuolization and myofibrillar loss in 
DIC. Next, we scrutinized the effects of transplanted CM 
or ES cells in DIC. We showed that CM or ES cells signifi-
cantly inhibit cytoplasmic vacuolization and myofibrillar 
loss in DIC compared with respective controls. Our data 
are in compliance with the previously published report on 
the carbon monoxide/heme oxygenase (CO/HO) system 
that inhibits cytoplasmic vacuolization and myofibrillar 
loss in DIC (34). In the present study, we confirmed evi-
dence of cytoplasmic vacuolization and myofibrillar loss 
and extended our findings by proving for the first time that 
CM or ES cells attenuate cytoplasmic vacuolization and 
myofibrillar loss in the DIC.
In our present study, we were unable to identify trans-
planted ES cells in the heart (data not shown); however, 
there were significant improvement in cardiac function, 
and therefore, we examined the role of c-kit+ve CSCs. We 
proposed that autocrine or paracrine factors released from 
ES cells will activate and differentiate resident CSCs 
into mature cardiac cell types and regenerate the DOX-
injured myocardium. CSCs are undifferentiated, self-
renewing, clonogenic, and capable of differentiating into 
all three major heart cell types both in vitro and in vivo 
(3). These cells have been identified and proven to regen-
erate infarcted myocardium (3). In the present study, we 
demonstrate increased levels of c-kit+ve CSCs following 
CM or ES cell transplantation compared with their con-
trols. Our data are in accordance with the previously pub-
lished studies showing c-kit+ve cells in the infarcted heart 
were up regulated and differentiated into cardiac myo-
cytes following treatment with HGF and IGF-1 growth 
factors (35). Therefore, we extended our findings and 
determined whether levels of HGF and IGF-1 are being 
affected in the DIC with or without CM or ES cell treat-
ment. To our surprise, we observed significant increased 
levels of HGF and IGF-1 growth factors in CM and ES 
cell-treated hearts compared with DOX, DOX + CC, and 
normal saline groups, suggesting these released factors 
might have played a significant role in their activation. 
Therefore, further studies are required to determine if 
more than two growth factors reported in this study are 
involved in the inhibition of multiple pathological condi-
tions observed in DIC.
Moreover, we determined whether transplantation of 
CM or ES cells contributes to improved cardiac function 
in DIC. In the present study, we have demonstrated that 2 
weeks post-DIC, mice transplanted with CM or ES cells 
had significantly improved cardiac function compared 
with DIC.
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In conclusion, this is the first study proposing that 
CM or ES cells have the competence to inhibit mul-
tiple pathological conditions such as cardiac myocyte 
apoptosis, Akt and ERK pathways, cardiac fibrosis, 
cytoplasmic vacuolization, and myofibrillar loss as well 
as upregulation of c-kit+ve CSCs and their differentia-
tion into cardiac myocytes along with improved cardiac 
function in DIC.
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